Reports from Newcastle University Provide New Insights into Hypertrophic Cardiomyopathy [Sacubitril/valsartan for the Treatment of Non-obstructive Hypertrophic Cardiomyopathy: an Open Label Randomized Controlled Trial (Silicofcm)].

A recent study conducted at Newcastle University in the United Kingdom examined the effects of sacubitril/valsartan treatment on patients with non-obstructive hypertrophic cardiomyopathy (HCM). The study, which involved 115 patients, found that after 16 weeks of treatment, there was no significant change in exercise capacity, cardiac structure, or function in the group receiving sacubitril/valsartan compared to the control group. The researchers concluded that while the treatment was well tolerated, it did not have a significant impact on HCM. This study provides valuable insights into the potential limitations of sacubitril/valsartan therapy for HCM. [Extracted from the article]